MedTrace Logo

A Study to Evaluate the Effect of Povorcitinib on the QT/QTc Interval in Healthy Participants

NCT06441318 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 128

Last updated 2024-09-25

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effect of povorcitinib on the QT/QTc Interval in healthy participants.

Conditions

  • Healthy Participants

Interventions

DRUG

Povorcitinib

Povorcitinib will be administered at protocol defined dose.

DRUG

Placebo

Placebo will be administered at protocol defined dose.

DRUG

Moxifloxacin

Moxifloxacin will be administered at protocol defined dose.

Sponsors & Collaborators

Principal Investigators

  • Incyte Medical Monitor · Incyte Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-07-12
Primary Completion
2024-09-10
Completion
2024-09-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06441318 on ClinicalTrials.gov